BiotechTube

Metoprolol- Toprol XL + Metoprolol- Lopressor

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myocardial Infarction

Conditions

Acute Myocardial Infarction

Trial Timeline

Feb 1, 2000 → Apr 1, 2002

NCT ID
NCT01523054

About Metoprolol- Toprol XL + Metoprolol- Lopressor

Metoprolol- Toprol XL + Metoprolol- Lopressor is a phase 1 stage product being developed by AstraZeneca for Acute Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT01523054. Target conditions include Acute Myocardial Infarction.

What happened to similar drugs?

20 of 20 similar drugs in Acute Myocardial Infarction were approved

Approved (20) Terminated (4) Active (0)
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
✅Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
✅micafungin + posaconazoleAstellas PharmaApproved
✅Selbex + SelbexEisaiApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01523054Phase 1Completed

Competing Products

20 competing products in Acute Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
AFM28AffimedPhase 1
11
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
SPT-07A injectionSinopharmPhase 3
36
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19